- Home
- RMBI vs GNLX Comparison
RMBI vs GNLX Comparison
Compare RMBI & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMBI | GNLX |
|---|---|---|
| Founded | 1887 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 124.8M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | RMBI | GNLX |
|---|---|---|
| Price | $13.25 | $2.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 17.4K | ★ 129.5K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | 1.10 | ★ 18.10 |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.80 | $1.99 |
| 52 Week High | $15.24 | $8.54 |
Technical Indicators
Market Signals| Indicator | RMBI | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.15 | 43.19 |
| Support Level | $13.02 | $2.54 |
| Resistance Level | $14.31 | $2.95 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 15.33 | 18.63 |
Price Performance
Historical ComparisonAbout RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.